Kamal N. Menghrajani

Hematology
27700 NW Freeway Ste 200
Cypress, TX 77433

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Targetable treatment resistance in thyroid cancer with clonal hematopoiesis.

Targetable treatment resistance in thyroid cancer with clonal hematopoiesis.

Journal: bioRxiv : the preprint server for biology
Published: October 17, 2024

Acute Myeloid Leukemia Presenting as Common Colds: An Uncommon Consideration.

Acute Myeloid Leukemia Presenting as Common Colds: An Uncommon Consideration.

Journal: Cureus
Published: January 30, 2024

Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.

Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.

Journal: Nature genetics
Published: December 20, 2023

Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors.

Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors.

Journal: JCO precision oncology
Published: August 10, 2023

Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia.

Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia.

Journal: Cell stem cell
Published: August 10, 2023

High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer.

High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer.

Journal: Blood advances
Published: July 19, 2023

Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination.

Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination.

Journal: Molecular cell
Published: August 19, 2022

Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.

Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.

Journal: American journal of hematology
Published: July 22, 2022

Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.

Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.

Journal: Leukemia & lymphoma
Published: September 03, 2021

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Journal: Nature medicine
Published: May 05, 2021

Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.

Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.

Journal: Blood advances
Published: March 31, 2021

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Journal: Nature medicine
Published: February 10, 2021
Showing 1-12 of 24

Last Updated: 09/26/2026